摘要
目的:分析颈段及胸上段食管癌患者,采取奈达铂与紫杉醇(白蛋白结合型)化疗同步适形调强放射治疗(IMRT)效果。方法:选取2021年1月—2023年6月泉州市第一医院60例颈段及胸上段食管癌患者为研究对象,基于随机数字表法分为两组,每组30例,对照组接受IMRT,研究组接受奈达铂与紫杉醇(白蛋白结合型)化疗同步IMRT治疗。观察两组不同治疗方案应用疗效与治疗前后的血清肿瘤标志物水平,以及治疗期间的不良反应发生率、生存情况差异。结果:同对照组相比,研究组有效率、疾病控制率高,研究组治疗后1个月血清肿瘤标志物表达水平低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。研究组1年生存率、研究组随访1年生存患者的卡氏功能状态(KPS)评分较对照组高(P<0.05)。结论:采取奈达铂与紫杉醇(白蛋白结合型)化疗同步IMRT治疗方案,有助于提升颈段及胸上段食管癌患者临床疗效,降低血清肿瘤标志物表达水平,有助于提升患者1年生存率。
Objective:To analyze the effect of Nedaplatin and Paclitaxel(Albumin-bound Type)chemotherapy combined with concurrent intensity-modulated radiotherapy(IMRT)in patients with cervical and upper thoracic esophageal cancer.Method:Sixty patients with cervical and upper thoracic esophageal cancer from Quanzhou First Hospital from January 2021 to June 2023 were selected as the research subjects.They were randomly divided into two groups based on a random number table method,with 30 patients in each group.The control group received IMRT,while the study group received Nedaplatin and Paclitaxel(Albumin-bound Type)chemotherapy combined with concurrent IMRT treatment.The efficacy of two different treatment regimens and the differences in serum tumor marker levels before and after treatment,as well as the incidence of adverse reactions during treatment and survival of the two groups were observed.Result:Compared with the control group,the effective rate and disease control rate of the study group were higher,the expression levels of serum tumor markers one month after treatment in the study group were lower than those in the control group(P<0.05).There were no statistically significant differences in the incidences of adverse reactions between the two groups(P>0.05).The 1-year survival rate of the study group,the Karnofsky performance status(KPS)score at one-year follow-up of the surviving patients in the study group was higher than that in the control group(P<0.05).Conclusion:The treatment regimen of Nedaplatin and Paclitaxel(Albumin-bound Type)chemotherapy combined with concurrent IMRT can help improve the clinical efficacy of patients with cervical and upper thoracic esophageal cancer,reduce the expression levels of serum tumor markers,and help increase the 1-year survival rate of patients.
作者
毛润芝
MAO Runzhi(Department of Radiotherapy,Quanzhou First Hospital,Quanzhou 362000,China)
出处
《中国医学创新》
2025年第25期40-44,共5页
Medical Innovation of China
关键词
紫杉醇(白蛋白结合型)
食管癌
适形调强放射治疗
肿瘤标志物
Paclitaxel(Albumin-bound Type)
Esophageal cancer
Intensity modulated radiation therapy
Tumor markers
作者简介
通信作者:毛润芝。
